End-of-day quote
Toronto S.E.
03:30:00 18/10/2021 am IST
|
5-day change
|
1st Jan Change
|
0.78
CAD
|
+9.86%
|
|
+50.00%
|
+173.68%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
50.48
|
43.96
|
24.27
|
55.04
|
34.46
|
24.12
|
Enterprise Value (EV)
1 |
47.43
|
50.83
|
31.95
|
56.56
|
42.44
|
37.34
|
P/E ratio
|
-3.96
x
|
-4.12
x
|
-3.39
x
|
-5.25
x
|
-2.82
x
|
-2.43
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
27.7
x
|
59.2
x
|
15.7
x
|
35.9
x
|
36.3
x
|
23.2
x
|
EV / Revenue
|
26
x
|
68.5
x
|
20.7
x
|
36.8
x
|
44.7
x
|
35.9
x
|
EV / EBITDA
|
-5.73
x
|
-5.76
x
|
-5.78
x
|
-7.87
x
|
-4.91
x
|
-4.28
x
|
EV / FCF
|
-7.44
x
|
-9.42
x
|
-7.04
x
|
-14.1
x
|
-6.71
x
|
-14.3
x
|
FCF Yield
|
-13.4%
|
-10.6%
|
-14.2%
|
-7.07%
|
-14.9%
|
-6.97%
|
Price to Book
|
5.05
x
|
151
x
|
-25.7
x
|
14.2
x
|
-10.1
x
|
-1.97
x
|
Nbr of stocks (in thousands)
|
93,477
|
93,527
|
1,10,340
|
1,54,403
|
1,74,646
|
1,74,658
|
Reference price
2 |
0.5400
|
0.4700
|
0.2200
|
0.3565
|
0.1973
|
0.1381
|
Announcement Date
|
22/03/19
|
26/03/20
|
25/03/21
|
24/03/22
|
29/03/23
|
21/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
1.824
|
0.742
|
1.544
|
1.535
|
0.95
|
1.039
|
EBITDA
1 |
-8.279
|
-8.832
|
-5.53
|
-7.191
|
-8.636
|
-8.725
|
EBIT
1 |
-8.998
|
-9.55
|
-6.264
|
-7.982
|
-9.413
|
-9.491
|
Operating Margin
|
-493.31%
|
-1,287.06%
|
-405.7%
|
-520%
|
-990.84%
|
-913.47%
|
Earnings before Tax (EBT)
1 |
-10.11
|
-10.66
|
-7.044
|
-9.318
|
-10.69
|
-9.927
|
Net income
1 |
-10.11
|
-10.66
|
-7.044
|
-9.312
|
-10.69
|
-9.927
|
Net margin
|
-554.17%
|
-1,436.66%
|
-456.22%
|
-606.64%
|
-1,125.26%
|
-955.44%
|
EPS
2 |
-0.1364
|
-0.1140
|
-0.0650
|
-0.0680
|
-0.0700
|
-0.0568
|
Free Cash Flow
1 |
-6.374
|
-5.398
|
-4.541
|
-3.998
|
-6.33
|
-2.602
|
FCF margin
|
-349.47%
|
-727.51%
|
-294.12%
|
-260.44%
|
-666.29%
|
-250.48%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
22/03/19
|
26/03/20
|
25/03/21
|
24/03/22
|
29/03/23
|
21/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
6.87
|
7.67
|
1.52
|
7.98
|
13.2
|
Net Cash position
1 |
3.04
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-0.7783
x
|
-1.388
x
|
-0.2111
x
|
-0.9245
x
|
-1.515
x
|
Free Cash Flow
1 |
-6.37
|
-5.4
|
-4.54
|
-4
|
-6.33
|
-2.6
|
ROE (net income / shareholders' equity)
|
-146%
|
-207%
|
2,135%
|
-638%
|
-4,772%
|
127%
|
ROA (Net income/ Total Assets)
|
-33.9%
|
-38.5%
|
-35.4%
|
-34.4%
|
-43.4%
|
-67.9%
|
Assets
1 |
29.81
|
27.72
|
19.92
|
27.09
|
24.62
|
14.62
|
Book Value Per Share
2 |
0.1100
|
0
|
-0.0100
|
0.0300
|
-0.0200
|
-0.0700
|
Cash Flow per Share
2 |
0.0700
|
0.0100
|
0.0100
|
0.0300
|
0.0100
|
0.0100
|
Capex
1 |
1.1
|
0.53
|
0.12
|
0.11
|
0.27
|
0.18
|
Capex / Sales
|
60.09%
|
70.75%
|
7.77%
|
7.04%
|
28.53%
|
17.32%
|
Announcement Date
|
22/03/19
|
26/03/20
|
25/03/21
|
24/03/22
|
29/03/23
|
21/03/24
|
|
1st Jan change
|
Capi.
|
---|
| +20.83% | 43.57B | | +22.27% | 22.7B | | +16.41% | 14.32B | | +11.11% | 13.42B | | +45.91% | 11.83B | | -6.86% | 6.98B | | -0.05% | 6.79B | | -8.87% | 5.73B | | +12.41% | 5.51B |
Generic Pharmaceuticals
|